aid: nouscom
name: Nouscom
description: >-
  Nouscom AG is a private, clinical-stage immuno-oncology company developing next-generation
  neoantigen-targeted cancer immunotherapies, founded in 2015 by Riccardo Cortese and Alfredo
  Nicosia, with headquarters in Basel, Switzerland and research and manufacturing operations in
  Rome, Italy. Its proprietary viral vector platform — great ape adenovirus and MVA vectors able to
  encode large neoantigen payloads together with other immunomodulators — is used to build both
  off-the-shelf and personalized cancer vaccines. The lead program, NOUS-209, targets 209 shared
  frameshift neoantigens for cancer interception in Lynch Syndrome carriers and for the treatment
  of dMMR/MSI metastatic colorectal cancer in combination with pembrolizumab; its second clinical
  program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. Nouscom raised an
  oversubscribed EUR 67.5 million Series C in November 2023, co-led by Andera Partners, Bpifrance
  (InnoBio 2) and M Ventures. Nouscom is a therapeutics developer, not a software vendor: it
  publishes no public API, developer portal, SDK or machine-readable API contract, and is profiled
  here as an identity-only record.
url: https://raw.githubusercontent.com/api-evangelist/nouscom/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: identity
x-tier-reason: no-api-surface
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Cancer Immunotherapy
- Switzerland
- Italy
- Private Company
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/nouscom-domain-security.yml
- type: LLMsTxt
  url: llms/nouscom-llms.txt
- type: Website
  url: https://nouscom.com/
- type: GitHubOrganization
  url: https://github.com/Nouscom
- type: LinkedIn
  url: https://www.linkedin.com/company/nouscom-ag/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Nouscom AG is a clinical-stage biotech whose product is a cancer immunotherapy, not
    software — it has no API host at all (api./dev./developer./docs./portal.nouscom.com are
    NXDOMAIN), its only public repository is R analysis code for the NOUS-209 Lynch Syndrome
    study, and its corporate WordPress site sits behind a SiteGround robot challenge that
    answers HTTP 202 to every path including /openapi.json.
  evidence:
  - url: https://api.nouscom.com/openapi.json
    status: 0
  - url: https://nouscom.com/openapi.json
    status: 202
  - url: https://nouscom.com/.well-known/agent-card.json
    status: 202
  - url: https://github.com/Nouscom
    status: 200
  checked: '2026-08-26'